Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab

Rheumatology (Oxford). 2021 Jun 18;60(6):e197-e199. doi: 10.1093/rheumatology/keaa832.

Authors

Ryoko Asano¹, Koichiro Shinoda¹, Reina Tsuda¹, Hiroyuki Hounoki¹, Masatoshi Kawataka¹, Teruhiko Makino², Johji Imura³, Yasuhito Hamaguchi⁴, Kazuyuki Tobe¹

Affiliations

¹ First Department of Internal Medicine, Toyama, Japan.
² Department of Dermatology, Toyama, Japan.
³ Department of Diagnostic Pathology, University of Toyama, Toyama, Japan.
⁴ Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

PMID: 33367923
DOI: 10.1093/rheumatology/keaa832

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Autoantibodies / blood*
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary
Chemoradiotherapy
Dermatomyositis / diagnosis
Dermatomyositis / immunology*
Epstein-Barr Virus Infections / complications
Humans
Hypothyroidism / chemically induced
Immune Checkpoint Inhibitors / administration & dosage
Immune Checkpoint Inhibitors / adverse effects
Male
Nasopharyngeal Neoplasms / therapy*
Nasopharyngeal Neoplasms / virology
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Transcription Factors / immunology*

Substances

Antineoplastic Agents, Immunological
Autoantibodies
Immune Checkpoint Inhibitors
TRIM33 protein, human
Transcription Factors
Nivolumab